Angelina Altshuler completed her degree in bioengineering PhD candidate at UC San Diego. Her research uses bioengineering approaches to study organ failure in circulatory shock. From her experiments, new insight has contributed to understanding organ dysfunction which may be applied to trauma, intensive care, neonatal, and transplant surgery patients. After her PhD, Angelina spent over six years at Illumina, the leader in genetic sequencing. She worked on HiSeqX ($1000 genome) consumables and over a dozen sequencing applications products from single cell to RNA and everything in between. In addition, she was involved in developing and implementing strategies for the consumable supply for key Illumina spin-out companies including Grail, Helix, Vitrolife, and CareDX while leading a large technical team. Angelina is now at Inscripta, a genome engineering company with a mission to revolutionize the way DNA editing is conducted.
Ph.D. , BioengineeringClass of 2013